Testing for discordance at metastatic relapse: Does it matter?

Journal of Clinical Oncology

Volumn 30, Issue 6, 2012, Pages 575-576

  Chia, Stephen ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; PARAFFIN; TRASTUZUMAB;

ASPIRATION BIOPSY; BREAST BIOPSY; BREAST CANCER; CANCER DIAGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL STUDY; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; PATIENT SATISFACTION; PRIORITY JOURNAL; TUMOR BIOPSY;

BIOPSY; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 84857530615     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.6385     Document Type: Editorial

References (16)

1. Amir E, Miller N, Geddie W, et al: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 30:587-592, 2012
2. Niikura N, Liu J, Hayashi N, et al: Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30:593-599, 2012
3. Regitnig P, Schippinger W, Lindbauer M, et al: Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 203:918-929, 2004
4. Li BD, Byskosh A, Molteni A, et al: Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 57:71-77, 1994 (Pubitemid 24299653)
5. Liedtke C, Broglio K, Moulder S, et al: Prognostic impact of discordance between triple receptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953-1958, 2009
6. Karlsson E, Lindström LS, Wilking U, et al: Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 28:116s, 2011 (suppl 15; abstr 1009)
7. MacFarlane R, Speers C, Masoudi H, et al: Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. J Clin Oncol 26:41s, 2008 (suppl 15; abstr 1000)
8. Gutierrez MC, Detre S, Johnston S, et al: Molecular changes in tamoxifen resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469-2476, 2005 (Pubitemid 47050837)
9. Jordan LB, Purdie CA, Quinlan PR, et al: A prospective comparison of switches in biomarker status between primary and recurrent breast cancer: The Breast Recurrence in Tissues Study (BRITS). Cancer Res 69, 2009 (suppl; abstr 4053)
10. Huddock JA, Hanau CA, Christen R, et al: Expression of estrogen and progesterone receptors in cytologic specimens using various fixatives. Diagn Cytopathol 15:78-83, 1996 (Pubitemid 26227125)
11. Engel KB, Moore HM: Effects of pre-analytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Path Lab Med 135:537-543, 2011
12. Perez EA, Suman VJ, Davidson NE, et al: HER2 testing by local, central and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 24:3032-3038, 2006 (Pubitemid 46638937)
13. Perez EA, Dueck AC, Press MF, et al: Round-robin review of HER2 testing in the context of adjuvant therapy for breast cancer (NCCTG N9831/BCIRG006/ BCIRG005). Cancer Res 70, 2010 (suppl; abstr PD10-02)
14. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
15. Shah SP, Morin RD, Khattra J, et al: Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461:809-813, 2009
16. Navin N, Krasnitz A, Rodgers L, et al: Inferring tumor progression from genomic heterogeneity. Genome Res 20:68-80, 2010